Latha M. Malaiyandi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Latha M. Malaiyandi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Kirk E. Dineley
Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
10 shared publications - Ian J. Reynolds
Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
3 shared publications - Amy Buros Stein
ACUTE Center at Denver Health Denver Colorado USA
2 shared publications - Bo Wang
Chicago College of Osteopathic Medicine Midwestern University Downers Grove, IL United States
2 shared publications Gordon L. Rintoul
2 shared publicationsHarsh Sharthiya
Department of Anatomy, Midwestern University, Downers Grove, IL, 60515, USA
2 shared publications
Latest Publications
- Open Access
- 21 November 2019
- Published by Springer Nature in BioMetals
- Vol. 32 (6) , 951-964
Using FluoZin-3 and fura-2 to monitor acute accumulation of free intracellular Cd2+ in a pancreatic beta cell line
The understanding of cellular Cd2+accumulation and toxicity is hampered by a lack of fluorescent indicators selective for intracellular free Cd2+([Cd2+]i). In this study, we used depolarized MIN6 mouse pancreatic beta cells as a model for evaluating [Cd2+]idetection with commercially available fluorescent probes, most of which have been traditionally used to visualize [Ca2+]iand [Zn2+]i. We trialed a panel of 12 probes including fura-2, FluoZin-3, Leadmium Green, Rhod-5N, indo-1, Fluo-5N, and others. We found that the [Zn2+]iprobe FluoZin-3 and the traditional [Ca2+]iprobe fura-2 responded most consistently and robustly to [Cd2+]iaccumulation mediated by voltage-gated calcium channels. While selective detection of [Cd2+]iby fura-2 required the omission of Ca2+from extracellular buffers, FluoZin-3 responded to [Cd2+]isimilarly in the presence or absence of extracellular Ca2+. Furthermore, we showed that FluoZin-3 and fura-2 can be used together for simultaneous monitoring of [Ca2+]iand [Cd2+]iin the same cells. None of the other fluorophores tested were effective [Cd2+]idetectors in this model.
- 21 November 2019
- Published by Springer Nature in BioMetals
- Vol. 32 (6) , 951-964
Open AccessUsing FluoZin-3 and fura-2 to monitor acute accumulation of free intracellular Cd2+ in a pancreatic beta cell line
The understanding of cellular Cd2+accumulation and toxicity is hampered by a lack of fluorescent indicators selective for intracellular free Cd2+([Cd2+]i). In this study, we used depolarized MIN6 mouse pancreatic beta cells as a model for evaluating [Cd2+]idetection with commercially available fluorescent probes, most of which have been traditionally used to visualize [Ca2+]iand [Zn2+]i. We trialed a panel of 12 probes including fura-2, FluoZin-3, Leadmium Green, Rhod-5N, indo-1, Fluo-5N, and others. We found that the [Zn2+]iprobe FluoZin-3 and the traditional [Ca2+]iprobe fura-2 responded most consistently and robustly to [Cd2+]iaccumulation mediated by voltage-gated calcium channels. While selective detection of [Cd2+]iby fura-2 required the omission of Ca2+from extracellular buffers, FluoZin-3 responded to [Cd2+]isimilarly in the presence or absence of extracellular Ca2+. Furthermore, we showed that FluoZin-3 and fura-2 can be used together for simultaneous monitoring of [Ca2+]iand [Cd2+]iin the same cells. None of the other fluorophores tested were effective [Cd2+]idetectors in this model.
- Open Access
- 8 November 2019
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 21 (11) , e13371
Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study
Background: Patient online drug reviews are a resource for other patients seeking information about the practical benefits and drawbacks of drug therapies. Patient reviews may also serve as a source of postmarketing safety data that are more user-friendly than regulatory databases. However, the reliability of online reviews has been questioned, because they do not undergo professional review and lack means of verification. Objective: We evaluated online reviews of hypnotic medications, because they are commonly used and their therapeutic efficacy is particularly amenable to patient self-evaluation. Our primary objective was to compare the types and frequencies of adverse events reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) with analogous information in patient reviews on the consumer health website Drugs.com. The secondary objectives were to describe patient reports of efficacy and adverse events and assess the influence of medication cost, effectiveness, and adverse events on user ratings of hypnotic medications. Methods: Patient ratings and narratives were retrieved from 1407 reviews on Drugs.com between February 2007 and March 2018 for eszopiclone, ramelteon, suvorexant, zaleplon, and zolpidem. Reviews were coded to preferred terms in the Medical Dictionary for Regulatory Activities. These reviews were compared to 5916 cases in the FAERS database from January 2015 to September 2017. Results: Similar adverse events were reported to both Drugs.com and FAERS. Both resources identified a lack of efficacy as a common complaint for all five drugs. Both resources revealed that amnesia commonly occurs with eszopiclone, zaleplon, and zolpidem, while nightmares commonly occur with suvorexant. Compared to FAERS, online reviews of zolpidem reported a much higher frequency of amnesia and partial sleep activities. User ratings were highest for zolpidem and lowest for suvorexant. Statistical analyses showed that patient ratings are influenced by considerations of efficacy and adverse events, while drug cost is unimportant. Conclusions: For hypnotic medications, online patient reviews and FAERS emphasized similar adverse events. Online reviewers rated drugs based on perception of efficacy and adverse events. We conclude that online patient reviews of hypnotics are a valid source that can supplement traditional adverse event reporting systems.
- 8 November 2019
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 21 (11) , e13371
Open AccessAdverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study
Background: Patient online drug reviews are a resource for other patients seeking information about the practical benefits and drawbacks of drug therapies. Patient reviews may also serve as a source of postmarketing safety data that are more user-friendly than regulatory databases. However, the reliability of online reviews has been questioned, because they do not undergo professional review and lack means of verification. Objective: We evaluated online reviews of hypnotic medications, because they are commonly used and their therapeutic efficacy is particularly amenable to patient self-evaluation. Our primary objective was to compare the types and frequencies of adverse events reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) with analogous information in patient reviews on the consumer health website Drugs.com. The secondary objectives were to describe patient reports of efficacy and adverse events and assess the influence of medication cost, effectiveness, and adverse events on user ratings of hypnotic medications. Methods: Patient ratings and narratives were retrieved from 1407 reviews on Drugs.com between February 2007 and March 2018 for eszopiclone, ramelteon, suvorexant, zaleplon, and zolpidem. Reviews were coded to preferred terms in the Medical Dictionary for Regulatory Activities. These reviews were compared to 5916 cases in the FAERS database from January 2015 to September 2017. Results: Similar adverse events were reported to both Drugs.com and FAERS. Both resources identified a lack of efficacy as a common complaint for all five drugs. Both resources revealed that amnesia commonly occurs with eszopiclone, zaleplon, and zolpidem, while nightmares commonly occur with suvorexant. Compared to FAERS, online reviews of zolpidem reported a much higher frequency of amnesia and partial sleep activities. User ratings were highest for zolpidem and lowest for suvorexant. Statistical analyses showed that patient ratings are influenced by considerations of efficacy and adverse events, while drug cost is unimportant. Conclusions: For hypnotic medications, online patient reviews and FAERS emphasized similar adverse events. Online reviewers rated drugs based on perception of efficacy and adverse events. We conclude that online patient reviews of hypnotics are a valid source that can supplement traditional adverse event reporting systems.
- Open Access
- 15 January 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study (Preprint)
BACKGROUND Patient online drug reviews are a resource for other patients seeking information about the practical benefits and drawbacks of drug therapies. Patient reviews may also serve as a source of postmarketing safety data that are more user-friendly than regulatory databases. However, the reliability of online reviews has been questioned, because they do not undergo professional review and lack means of verification. OBJECTIVE We evaluated online reviews of hypnotic medications, because they are commonly used and their therapeutic efficacy is particularly amenable to patient self-evaluation. Our primary objective was to compare the types and frequencies of adverse events reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) with analogous information in patient reviews on the consumer health website Drugs.com. The secondary objectives were to describe patient reports of efficacy and adverse events and assess the influence of medication cost, effectiveness, and adverse events on user ratings of hypnotic medications. METHODS Patient ratings and narratives were retrieved from 1407 reviews on Drugs.com between February 2007 and March 2018 for eszopiclone, ramelteon, suvorexant, zaleplon, and zolpidem. Reviews were coded to preferred terms in the Medical Dictionary for Regulatory Activities. These reviews were compared to 5916 cases in the FAERS database from January 2015 to September 2017. RESULTS Similar adverse events were reported to both Drugs.com and FAERS. Both resources identified a lack of efficacy as a common complaint for all five drugs. Both resources revealed that amnesia commonly occurs with eszopiclone, zaleplon, and zolpidem, while nightmares commonly occur with suvorexant. Compared to FAERS, online reviews of zolpidem reported a much higher frequency of amnesia and partial sleep activities. User ratings were highest for zolpidem and lowest for suvorexant. Statistical analyses showed that patient ratings are influenced by considerations of efficacy and adverse events, while drug cost is unimportant. CONCLUSIONS For hypnotic medications, online patient reviews and FAERS emphasized similar adverse events. Online reviewers rated drugs based on perception of efficacy and adverse events. We conclude that online patient reviews of hypnotics are a valid source that can supplement traditional adverse event reporting systems.
- 15 January 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAdverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study (Preprint)
BACKGROUND Patient online drug reviews are a resource for other patients seeking information about the practical benefits and drawbacks of drug therapies. Patient reviews may also serve as a source of postmarketing safety data that are more user-friendly than regulatory databases. However, the reliability of online reviews has been questioned, because they do not undergo professional review and lack means of verification. OBJECTIVE We evaluated online reviews of hypnotic medications, because they are commonly used and their therapeutic efficacy is particularly amenable to patient self-evaluation. Our primary objective was to compare the types and frequencies of adverse events reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) with analogous information in patient reviews on the consumer health website Drugs.com. The secondary objectives were to describe patient reports of efficacy and adverse events and assess the influence of medication cost, effectiveness, and adverse events on user ratings of hypnotic medications. METHODS Patient ratings and narratives were retrieved from 1407 reviews on Drugs.com between February 2007 and March 2018 for eszopiclone, ramelteon, suvorexant, zaleplon, and zolpidem. Reviews were coded to preferred terms in the Medical Dictionary for Regulatory Activities. These reviews were compared to 5916 cases in the FAERS database from January 2015 to September 2017. RESULTS Similar adverse events were reported to both Drugs.com and FAERS. Both resources identified a lack of efficacy as a common complaint for all five drugs. Both resources revealed that amnesia commonly occurs with eszopiclone, zaleplon, and zolpidem, while nightmares commonly occur with suvorexant. Compared to FAERS, online reviews of zolpidem reported a much higher frequency of amnesia and partial sleep activities. User ratings were highest for zolpidem and lowest for suvorexant. Statistical analyses showed that patient ratings are influenced by considerations of efficacy and adverse events, while drug cost is unimportant. CONCLUSIONS For hypnotic medications, online patient reviews and FAERS emphasized similar adverse events. Online reviewers rated drugs based on perception of efficacy and adverse events. We conclude that online patient reviews of hypnotics are a valid source that can supplement traditional adverse event reporting systems.
- Open Access
- 28 June 2018
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 478, 1-9
M3-subtype muscarinic receptor activation stimulates intracellular calcium oscillations and aldosterone production in human adrenocortical HAC15 cells
- 28 June 2018
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 478, 1-9
Open AccessM3-subtype muscarinic receptor activation stimulates intracellular calcium oscillations and aldosterone production in human adrenocortical HAC15 cells
- 3 June 2016
- Published by Springer Nature in BioMetals
- Vol. 29 (4) , 625-635
Fluorescence detection of intracellular cadmium with Leadmium Green
Leadmium Green is a commercially available, small molecule, fluorescent probe advertised as a detector of free intracellular cadmium (Cd2+) and lead (Pb2+). Leadmium Green has been used in various paradigms, such as tracking Cd2+ sequestration in plant cells, heavy metal export in protozoa, and Pb2+ absorption by vascular endothelial cells. However very little information is available regarding its affinity and selectivity for Cd2+, Pb2+, and other metals. We evaluated the in vitro selectivity of Leadmium Green using spectrofluorimetry. Consistent with manufacturer’s claims, Leadmium Green was sensitive to Cd2+ (KD ~600 nM) and also Pb2+ (KD ~9.0 nM) in a concentration-dependent manner, and furthermore proved insensitive to Ca2+, Co2+, Mn2+ and Ni2+. Leadmium Green also responded to Zn2+ with a KD of ~82 nM. Using fluorescence microscopy, we evaluated Leadmium Green in live mouse hippocampal HT22 cells. We demonstrated that Leadmium Green detected ionophore-mediated acute elevations of Cd2+ or Zn2+ in a concentration-dependent manner. However, the maximum fluorescence produced by ionophore-delivered Zn2+ was much less than that produced by Cd2+. When tested in a model of oxidant-induced liberation of endogenous Zn2+, Leadmium Green responded weakly. We conclude that Leadmium Green is an effective probe for monitoring intracellular Cd2+, particularly in models where Cd2+ accumulates rapidly, and when concomitant fluctuations of intracellular Zn2+ are minimal.
- 3 June 2016
- Published by Springer Nature in BioMetals
- Vol. 29 (4) , 625-635
Fluorescence detection of intracellular cadmium with Leadmium Green
Leadmium Green is a commercially available, small molecule, fluorescent probe advertised as a detector of free intracellular cadmium (Cd2+) and lead (Pb2+). Leadmium Green has been used in various paradigms, such as tracking Cd2+ sequestration in plant cells, heavy metal export in protozoa, and Pb2+ absorption by vascular endothelial cells. However very little information is available regarding its affinity and selectivity for Cd2+, Pb2+, and other metals. We evaluated the in vitro selectivity of Leadmium Green using spectrofluorimetry. Consistent with manufacturer’s claims, Leadmium Green was sensitive to Cd2+ (KD ~600 nM) and also Pb2+ (KD ~9.0 nM) in a concentration-dependent manner, and furthermore proved insensitive to Ca2+, Co2+, Mn2+ and Ni2+. Leadmium Green also responded to Zn2+ with a KD of ~82 nM. Using fluorescence microscopy, we evaluated Leadmium Green in live mouse hippocampal HT22 cells. We demonstrated that Leadmium Green detected ionophore-mediated acute elevations of Cd2+ or Zn2+ in a concentration-dependent manner. However, the maximum fluorescence produced by ionophore-delivered Zn2+ was much less than that produced by Cd2+. When tested in a model of oxidant-induced liberation of endogenous Zn2+, Leadmium Green responded weakly. We conclude that Leadmium Green is an effective probe for monitoring intracellular Cd2+, particularly in models where Cd2+ accumulates rapidly, and when concomitant fluctuations of intracellular Zn2+ are minimal.
- 2 April 2013
- Published by Springer Nature
- p. 861-913
Drugs to Treat Head and Neck Cancers: Mechanisms of Action
- 2 April 2013
- Published by Springer Nature
- p. 861-913
Drugs to Treat Head and Neck Cancers: Mechanisms of Action
- 1 May 2009
- Published by Elsevier in Cell Calcium
- Vol. 45 (5) , 447-455
A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition
- 1 May 2009
- Published by Elsevier in Cell Calcium
- Vol. 45 (5) , 447-455
A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition
- Open Access
- 12 October 2005
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 25 (41) , 9507-9514
Zn2+Inhibits Mitochondrial Movement in Neurons by Phosphatidylinositol 3-Kinase Activation
Mitochondria have been identified as targets of the neurotoxic actions of zinc, possibly through decreased mitochondrial energy production and increased reactive oxygen species accumulation. It has been hypothesized that impairment of mitochondrial trafficking may be a mechanism of neuronal injury. Here, we report that elevated intraneuronal zinc impairs mitochondrial trafficking. At concentrations just sufficient to cause injury, zinc rapidly inhibited mitochondrial movement without altering morphology. Zinc chelation initially restored movement, but the actions of zinc became insensitive to chelator in <10 min. A search for downstream signaling events revealed that inhibitors of phosphatidylinositol (PI) 3-kinase prevented this zinc effect on movement. Moreover, transient inhibition of PI 3-kinase afforded neuroprotection against zinc-mediated toxicity. These data illustrate a novel mechanism that regulates mitochondrial trafficking in neurons and also suggest that mitochondrial trafficking may be closely coupled to neuronal viability.
- 12 October 2005
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 25 (41) , 9507-9514
Open AccessZn2+Inhibits Mitochondrial Movement in Neurons by Phosphatidylinositol 3-Kinase Activation
Mitochondria have been identified as targets of the neurotoxic actions of zinc, possibly through decreased mitochondrial energy production and increased reactive oxygen species accumulation. It has been hypothesized that impairment of mitochondrial trafficking may be a mechanism of neuronal injury. Here, we report that elevated intraneuronal zinc impairs mitochondrial trafficking. At concentrations just sufficient to cause injury, zinc rapidly inhibited mitochondrial movement without altering morphology. Zinc chelation initially restored movement, but the actions of zinc became insensitive to chelator in <10 min. A search for downstream signaling events revealed that inhibitors of phosphatidylinositol (PI) 3-kinase prevented this zinc effect on movement. Moreover, transient inhibition of PI 3-kinase afforded neuroprotection against zinc-mediated toxicity. These data illustrate a novel mechanism that regulates mitochondrial trafficking in neurons and also suggest that mitochondrial trafficking may be closely coupled to neuronal viability.
- Open Access
- 26 April 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 93 (5) , 1242-1250
Direct visualization of mitochondrial zinc accumulation reveals uniporter‐dependent and ‐independent transport mechanisms
Current evidence suggests that zinc kills neurons by disrupting energy production, specifically by inhibiting mitochondrial function. However it is unclear if the inhibitory effect requires zinc accumulation, and if so, precisely how zinc enters mitochondria. Here, using fluorescence microscopy to visualize individual rat brain mitochondria, we detected matrix zinc uptake using the fluorophore FluoZin‐3. Fluorescence increased rapidly in mitochondria treated with micromolar free zinc, and was quickly returned to baseline by membrane permeant chelation. Zinc uptake occurred through the calcium uniporter, because depolarization or uniporter blockade reduced fluorescence changes. However, increased fluorescence under these conditions suggests that zinc can enter through a uniporter‐independent pathway. Fluorescence steadily declined over time and was unaffected by acidification or phosphate depletion, suggesting that zinc precipitation is not a mechanism for reducing matrix zinc. Uniporter blockade with ruthenium red also did not change the rate of zinc loss. Instead, zinc appears to exit the matrix through a novel efflux pathway not yet identified. Interestingly, dye‐loaded mitochondria showed no fluorescence increase after treatment with strong oxidants, arguing against oxidant‐labile intra‐mitochondrial zinc pools. This study is the first to directly demonstrate zinc accumulation in individual mitochondria and provides insight about mechanisms mediating mitochondrial zinc uptake and efflux.
- 26 April 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 93 (5) , 1242-1250
Open AccessDirect visualization of mitochondrial zinc accumulation reveals uniporter‐dependent and ‐independent transport mechanisms
Current evidence suggests that zinc kills neurons by disrupting energy production, specifically by inhibiting mitochondrial function. However it is unclear if the inhibitory effect requires zinc accumulation, and if so, precisely how zinc enters mitochondria. Here, using fluorescence microscopy to visualize individual rat brain mitochondria, we detected matrix zinc uptake using the fluorophore FluoZin‐3. Fluorescence increased rapidly in mitochondria treated with micromolar free zinc, and was quickly returned to baseline by membrane permeant chelation. Zinc uptake occurred through the calcium uniporter, because depolarization or uniporter blockade reduced fluorescence changes. However, increased fluorescence under these conditions suggests that zinc can enter through a uniporter‐independent pathway. Fluorescence steadily declined over time and was unaffected by acidification or phosphate depletion, suggesting that zinc precipitation is not a mechanism for reducing matrix zinc. Uniporter blockade with ruthenium red also did not change the rate of zinc loss. Instead, zinc appears to exit the matrix through a novel efflux pathway not yet identified. Interestingly, dye‐loaded mitochondria showed no fluorescence increase after treatment with strong oxidants, arguing against oxidant‐labile intra‐mitochondrial zinc pools. This study is the first to directly demonstrate zinc accumulation in individual mitochondria and provides insight about mechanisms mediating mitochondrial zinc uptake and efflux.
- 1 August 2004
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 36 (4) , 283-286
Mitochondrial Trafficking in Neurons: A Key Variable in Neurodegeneration?
Mitochondria are the proximate target of a number of different neurotoxins. Typically, impairing of the key bioenergetic function of mitochondria by toxins is considered as the main mechanism of action. However, the effective maintenance of energy generation in neurons depends on the biogenesis, trafficking, and degradation of mitochondria in addition to the traditional bioenergetic functions. We have recently demonstrated that glutamate alters both the trafficking and morphology of mitochondria in primary neurons. In addition, several other potential neurotoxins, including nitric oxide and zinc, inhibit mitochondrial movement and, in some cases, alter morphology too. This suggests that some part of the action of neurotoxins might include the impairment of mitochondrial trafficking in neurons, with the resultant failure of local ATP delivery.
- 1 August 2004
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 36 (4) , 283-286
Mitochondrial Trafficking in Neurons: A Key Variable in Neurodegeneration?
Mitochondria are the proximate target of a number of different neurotoxins. Typically, impairing of the key bioenergetic function of mitochondria by toxins is considered as the main mechanism of action. However, the effective maintenance of energy generation in neurons depends on the biogenesis, trafficking, and degradation of mitochondria in addition to the traditional bioenergetic functions. We have recently demonstrated that glutamate alters both the trafficking and morphology of mitochondria in primary neurons. In addition, several other potential neurotoxins, including nitric oxide and zinc, inhibit mitochondrial movement and, in some cases, alter morphology too. This suggests that some part of the action of neurotoxins might include the impairment of mitochondrial trafficking in neurons, with the resultant failure of local ATP delivery.